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r13Cd-NMR studies of solutions of cadmium-loaded calmodulin (Cd,CaM) and the tetradecapeptide masto- 
paran in different ratios show that mastoparan binds to Cd,CaM with high affinity. The off-rate of protein- 
bound mastoparan is found to be 40 s-r or less. The binding of one molecule of mastoparan to Cd,CaM 
is observed to affect all four metal-binding sites, indicating that both the N-terminal and C-terminal globular 
domains of the protein undergo conformational changes. 
Mastoparan Calmodulin Peptide-calmodulin interaction Calmodulin-binding peptide “Td-NMR 
1. INTRODUCTION 
Calmodulin (CaM) is a ubiquitous Ca’+-binding 
protein that is known to regulate a wide variety of 
cellular functions [ 11. On a molecular level the 
regulating effect is accomplished through the in- 
teraction of CaM with enzymes, the activity of 
which is then increased or decreased [2]. There are 
few details available on these interactions, 
although several lines of evidence have suggested 
that they depend to a large extent on hydrophobici- 
ty. It has for example been noted that a number of 
hydrophobic organic compounds, e.g. fluorescent 
molecular probes (9AC, ANS and TNS) and drugs 
(review [3]), bind to CaM in a Ca’+-dependent 
manner. Also it has been observed that CaM in- 
teracts with the hydrophobic support phenyl- 
Sepharose only in the presence of Ca2+ [4]. 
In addition to these hydrophobic organic com- 
pounds, a number of small naturally occurring 
Abbreviations: ACTH, adrenocorticotropic hormone; 
9AC, 9-anthroylcholine; ANS, 8-anilinonaphthalenesul- 
fonate; TNS, 2-p-toluidinylnaphthalene-6-sulfonate 
peptides with hydrophobic and basic properties 
bind to CaM with high affinity in a 
Ca2+-dependent manner, e.g. ,&endorphin [5], 
dynorphin and mastoparan [6], vasoactive in- 
testinal peptide (VIP), glucagon and ACTH [5], 
and also some venom peptides like melittin [7]. 
Although some of these peptide-CaM interac- 
tions may not play a physiological role, these pep- 
tides have nevertheless been considered as models 
for the CaM-binding regions on CaM-activated en- 
zymes. The recent discovery of what appears to be 
the calmodulin-binding domain of skeletal muscle 
myosin light chain kinase (MLCK) - an enzyme 
activated by CaM - has a bearing on this point [8]. 
A peptide, denoted M13, 27 residues in length, 
which represents the carboxy-terminal end of the 
enzyme, was found to bind to CaM in a 
Ca2+-dependent manner with a 1: 1 stoichiometry. 
Addition of the Ml3 peptide was found to inhibit 
the activation of MLCK by CaM with a Ki of 
0.9 nM 181. Although the Ml 3 peptide sequence 
does not have a high homology with the naturally 
occurring peptides mentioned above, they all share 
three structural features that appear to be of im- 
portance for interaction with CaM in its 
28 
Published by Elsevier Science Publishers B. V. (Biomedical Divrsion) 
0014.5793/86/$3.50 0 1986 Federation of European Biochemical Societies 
Volume 199. number 1 FEBS LETTERS April 1986 
Ca’+-loaded form: (i) clusters of basic residues; (ii) 
hydrophobic residues adjacent o the basic residues 
[5]; and (iii) a predicted high a-helical content 
[6,9,10]. In addition, the peptides compete for 
binding to CaM both with each other [5] and with 
CaM-regulated enzymes, e.g. MLCK [ll] and 
brain phosphodiesterase [IO]. It is therefore highly 
likely that these peptides and the CaM-regulated 
enzymes interact with CaM in a similar manner. It 
is thus of obvious interest to try to localize the 
peptide-binding sites on CaM and to assess possi- 
ble structural rearrangements accompanying this 
interaction. Circular dichroism (CD) studies of 
Ca&aM-peptide complexes, e.g. with the peptides 
mastoparan [12], Ml3 [13] and melittin [14], have 
revealed a higher a-helix content than the sum of 
that observed for Ca&aM and free peptide, 
separately. It is, however, difficult to separate a 
structural change occurring in the bound peptide 
from one taking place in CaM. Similar problems 
arise in ‘H-NMR studies where signals from the 
peptide will partly overlap and obscure those from 
CaM. 
Here we have employed ‘13Cd-NMR to follow 
the structural changes in the CaM molecule follow- 
ing the binding of the peptide mastoparan, a 
tetradecapeptide from vespid wasp [ 151. This ap- 
proach is based on the fact that Cd2+ can replace 
Ca2+ in its 4 binding sites without significant 
changes in the protein tertiary structure. In fact 
Cd&aM has been shown to activate a number of 
enzymes just like Ca&aM [16]. ‘13Cd-NMR spec- 
tral shifts are very sensitive to changes in the local 
structure around the metal ion, and furthermore, 
since ‘13Cd2+ is bound only to CaM, no problem 
of spectral overlap between signals from protein 
and peptide arise. 
2. MATERIALS AND METHODS 
CaM was isolated from bovine testes as de- 
scribed [17]. The purity of CaM was checked by 
SDS gel electrophoresis, agarose gel electrophore- 
sis and FPLC (Pro-RPC column, Pharmacia). 
The calcium-free form was prepared by passing 
a solution of 447 mg CaM in 3 ml Hz0 through a 
20 ml Chelex-100 (Bio-rad) column at pH 8. The 
residual calcium content was 0.05 mol Ca/mol 
CaM, as determined by atomic absorption spec- 
troscopy. The calcium-free protein was first freeze- 
dried and then redissolved in DzO at pH 7. 
Mastoparan was obtained from Bachem (Tor- 
rance, CA) (lot no.7218) and used without further 
purification. 
‘13Cd experiments were performed at 24 + 1°C 
on a home-built 6 T NMR spectrometer (for a 
description see [18]), at 56.55 MHz using routine 
acquisition parameters described elsewhere [ 191. A 
30 Hz line-broadening function was used to im- 
prove the signal-to-noise ratio. Spectral shifts are 
reported relative to 0.1 M “3CdC104 at pH 7. 
i13Cd was added to CaM in the form of CdNO3 
solution, prepared from Cd metal (US Services 
Inc.) and HNO3. The isotope enrichment of ‘13Cd 
-80 -xx) -la -14oppn -80 -loo -120 -14oppm 
Fig.1. “‘Cd-NMR spectra of a 1 mM solution of 
C&CaM with increasing amounts of mastoparan added. 
The molar ratio of mastoparan to CaM is indicated on 
each spectrum. 
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Table 1 
Amino acid sequences of the CaM-binding peptides M 13, mastoparan and mastoparan X 
Ml3 K-R-R-W-K-K_N-F-I-A-V-S-A-A-N-I&F-K-K_I-S-S-S-G-A-L-M 
Mastoparan I-N-L-&A-L-A-A-L-A-K-&I-L-NH2 
Mastoparan X I-N-W&-G-I-A-A-M-A-I&&L-L-NH2 
One-letter codes used: A (alanine), R (arginine), N (asparagine), G (glycine), I
(isoleucine), L (leucine), K (lysine), M (methionine), F (phenylalanine), S (serine), W 
(tryptophan) and V (valine). Basic residues are underlined 
Titration of CQCaM with mastoparan was per- 
formed in a 3 ml DzO solution containing 1 mM 
Cd&aM at pH 7. Mastoparan was added in ali- 
quots of 2O,ul, corresponding to l/7 mol peptide 
per mol protein, up to a molar ratio of 1: 1. Two 
independent titrations gave virtually the same spec- 
tral changes. The second titration was continued 
up to 2 mol peptide per mol CdgCaM. 
3. RESULTS 
In the absence of peptide, two i13Cd-NMR 
signals (at - 87 and - 114 ppm) are observed for 
a solution of Cd4CaM (fig.la). These signals arise 
from ’ 13Cd2+ bound to the two strong binding sites 
III and IV. The ‘13Cd2+ in the weaker binding sites 
I and II gives no signals, probably due to rapid in- 
terconversions on the time scale of at least 
103-lo4 s-l between two different conformations 
in the N-terminal domain containing sites I and II 
]201* 
When mastoparan is added 4 new signals (at 
- 102, - 111, - 112 and - 121 ppm) start to ap- 
pear in the ’ 13Cd-NMR spectrum (fig. 1 b-e). At in- 
termediate ratios of peptide to C&CaM, 6 sharp 
signals are observed, and at molar ratios of 1: 1 
and higher, only the 4 new signals of approximate- 
ly the same intensity remain in the spectrum. The 
relative intensities of the two sets of signals, cor- 
responding to C&CaM with and without 
mastoparan bound, are linearly related to the 
molar ratio of mastoparan to C&CaM. 
At a molar ratio of peptide to Cd4CaM of 2: 1, 
all 4 signals in the ’ 13Cd-NMR spectrum are 
broadened, but remain at the same shifts as after 
addition of the first equivalent (fig.lf-h). 
4. DISCUSSION 
The linear dependence of the intensities of the 
two sets of signals in the 113Cd-NMR spectra on 
the molar ratio of mastoparan to CQCaM ob- 
served when mastoparan is successively added to 
Cd4CaM clearly indicates that mastoparan is 
bound to CaM with high affinity. This is in good 
agreement with a dissociation constant of 0.3 nM 
for the mastoparan-Ca&aM complex [6], deter- 
mined by competition experiments with smooth 
muscle MLCK. The Ca&aM-bound MLCK was 
monitored by 9AC fluorescence. 
The exchange of free and protein-bound peptide 
is slow on the NMR time scale. The “‘Cd-NMR 
signal linewidths give an upper limit of the ex- 
change rate of 40 s-l. 
The finding that 4 new signals appear in the 
‘13Cd-NMR spectrum when 1 mol mastoparan/ 
mol C&CaM is added clearly shows that a bound 
mastoparan molecule is able to induce conforma- 
tional changes that affect all 4 Ca2+-binding sites 
in CaM. ‘H-NMR studies have shown that binding 
of Ml3 to Ca.&aM causes dramatic changes in the 
‘H-NMR spectrum, with signals arising from pro- 
tons in both halves of CaM affected [13]. 
In this respect, the peptides differ markedly 
from different small drug molecules like 
trifluoperazine, felodipine and diltiazem, for 
which both halves of CaM are affected only after 
addition of 2 or more mol drug/m01 C&CaM [21]. 
The unavailability of high-resolution X-ray 
coordinates for CaM makes it difficult to propose 
a detailed model for the mastoparan-Ca&aM 
complex. However, inspection of similarities with 
small drugs and other peptides that bind to CaM 
with high affinity could give some clues to the 
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specific interactions involved. It has been proposed 
that the major tranquillizers interact with both 
negative charges and hydrophobic regions of the 
amphiphilic helices of CaM [22], for example the 
amphiphilic helix between residues 82 and 92 of 
bovine brain CaM, which contains 4 glutamic acid 
and 2 phenylalanine residues. This region makes 
up about half of the long helix connecting the 2 
Ca’+-binding domains of CaM, as seen in the 
crystal structure [23]. 
In an attempt o-localize the peptide-binding site 
of Ca&aM, the tryptophan-containing peptide 
mastoparan X was titrated with CaM or 1 of the 3 
CaM fragments containing residues l-106,72-148 
and 107-148, in the presence of Ca2+ [7]. The 
complex formation was monitored by fluorescence 
anisotropy and it was suggested that the CaM 
region made up of residues 72-106 contains a ma- 
jor portion of the peptide-binding site of Ca&aM 
[7]. This region includes most of the long a-helix 
(residues 65-92) connecting the 2 globular do- 
mains of Ca4CaM. The anionic sequence at posi- 
tions 78-84, which contains 2 aspartic acid and 3 
glutamic acid residues, has been proposed to in- 
teract with the basic regions found in all high- 
affinity CaM-binding peptides, permitting interac- 
tion between hydrophobic peptide regions and the 
non-polar CaM residues 88-92 [7]. Also, signifi- 
cant reduction of the reactivities of the amino 
groups of Lys 75 and 148 of CaM has been ob- 
served upon binding of ,&endorphin to Ca&aM at 
a molar ratio of 2.5 : 1 [24]. 
The 16residue peptide mastoparan is sufficient- 
ly large to bind to Ca&aM in such a way that it is 
in contact with both the N-terminal and C-terminal 
domains of Ca&aM simultaneously. Mastoparan 
has a predicted high m-helical content in aqueous 
solution [6]. CD studies have indicated that the U- 
helical content of mastoparan is low in aqueous 
solution, but 55% in 70% trifluoroethanol/water 
mixture and the total a-helical content of Ca,&aM 
and the peptide has been shown to increase upon 
formation of a complex [12]. It therefore seems 
reasonable to assume that the secondary structure 
of C&CaM-bound mastoparan is mostly a-helix, 
which implies that the peptide would have a length 
of 21 A in its protein-bound form. From the X-ray 
crystal structure of Ca&aM [23], the minimum 
separation between the van der Waals’ surfaces of 
the two globular domains may be estimated to 
about 11 A (251. If the long a-helix connecting the 
two globular domains in the crystal structure of 
Ca&aM [23] is also present in solution, interaction 
of the basic, amphipathic peptide mastoparan with 
the acidic and hydrophobic regions of this long a- 
helix in Ca4CaM would permit mastoparan to in- 
teract with both globular domains. 
As mentioned above, the peptides M13, 
representing the CaM-binding region of MLCK, 
and mastoparan are similar in many respects, i.e. 
the occurrence in both of hydrophobic regions, 
positively charged patches and a high tendency of 
a-helix formation, together with comparable 
dissociation constants, Ca2+-dependent and com- 
petitive binding to Ca&aM and 1: 1 stoichiometry 
of the peptide-CazCaM complexes. This suggests 
that mastoparan could be used as a model peptide 
in the study of CaM-enzyme interactions. 
The observation that all 4 Ca’+-binding sites in 
CaM are affected by mastoparan binding indicates 
that both globular domains are involved in CaM- 
target enzyme interactions. It has indeed been 
shown that none of the tryptic CaM fragments 
l-77, l-90, l-106, 78-148 or 107-148 are able to 
activate the protein phosphatase, calcineurin or the 
Ca2+-dependent CAMP phosphodiesterase. How- 
ever, the fragment 78-148 was found to activate 
fully phosphorylase kinase, but with lower affinity 
than CaM [26]. 
The changes observed in the ‘13Cd-NMR spec- 
trum on continued titration of C&CaM from 1 to 
2 mol mastoparan/mol C&CaM show that a 
second peptide molecule may be bound to CaM. 
The shifts of the ‘13Cd-NMR signals are not af- 
fected by this second equivalent of mastoparan, in- 
dicating that the conformation of CaM remains 
the same as with only one peptide molecule bound. 
The broad signals suggest either or both weaker 
binding and faster exchange of the second equiv- 
alent of mastoparan than of the first. Binding of 
a second equivalent of peptide has been detected in 
covalent cross-linking experiments with &en- 
dorphin and CaM [27]. 
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